Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

Cancer Cell

Volumn 8, Issue 4, 2005, Pages 299-309

  Casanovas, Oriol ^a   Hicklin, Daniel J ^b   Bergers, Gabriele ^c   Hanahan, Douglas ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL MODEL; ARTICLE; CANCER STAGING; ENZYME INHIBITION; GROWTH INHIBITION; MOUSE; NONHUMAN; PANCREAS ISLET CELL TUMOR; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVASCULARIZATION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 26644471951     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2005.09.005     Document Type: Article

References (46)

1. T.E. Adams, S. Alpert, and D. Hanahan Non-tolerance and autoantibodies to a transgenic self antigen expressed in pancreatic β cells Nature 325 1987 223 228
2. G. Bergers, K. Javaherian, K.M. Lo, J. Folkman, and D. Hanahan Effects of angiogenesis inhibitors on multistage carcinogenesis in mice Science 284 1999 808 812
3. G. Bergers, R. Brekken, G. McMahon, T.H. Vu, T. Itoh, K. Tamaki, K. Tanzawa, P. Thorpe, S. Itohara, Z. Werb, and D. Hanahan Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis Nat. Cell Biol. 2 2000 737 744
4. G. Bergers, S. Song, N. Meyer-Morse, E. Bergsland, and D. Hanahan Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors J. Clin. Invest. 111 2003 1287 1295
5. D.M. Brantley, N. Cheng, E.J. Thompson, Q. Lin, R.A. Brekken, P.E. Thorpe, R.S. Muraoka, D.P. Cerretti, A. Pozzi, and D. Jackson Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo Oncogene 21 2002 7011 7026
6. H.J. Broxterman, J. Lankelma, and K. Hoekman Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences Drug Resist. Updat. 6 2003 111 127
7. N. Cheng, D. Brantley, W.B. Fang, H. Liu, W. Fanslow, D.P. Cerretti, K.N. Bussell, A. Reith, D. Jackson, and J. Chen Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors Neoplasia 5 2003 445 456
8. G. Christofori, P. Naik, and D. Hanahan Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis Mol. Endocrinol. 9 1995 1760 1770
9. A. Compagni, P. Wilgenbus, M.A. Impagnatiello, M. Cotten, and G. Christofori Fibroblast growth factors are required for efficient tumor angiogenesis Cancer Res. 60 2000 7163 7169
10. D. Daniel, N. Meyer-Morse, E.K. Bergsland, K. Dehne, L.M. Coussens, and D. Hanahan Immune enhancement of skin carcinogenesis by CD4+ T cells J. Exp. Med. 197 2003 1017 1028
11. D. Daniel, C. Chiu, E. Giraudo, M. Inoue, L.A. Mizzen, N.R. Chu, and D. Hanahan CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer Cancer Res. 65 2005 2018 2025
12. K.E. de Visser, L.V. Korets, and L.M. Coussens De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent Cancer Cell 7 2005 411 423
13. M. Dougher-Vermazen, J.D. Hulmes, P. Bohlen, and B.I. Terman Biological activity and phosphorylation sites of the bacterially expressed cytosolic domain of the KDR VEGF-receptor Biochem. Biophys. Res. Commun. 205 1994 728 738
14. S. Efrat, S. Linde, H. Kofod, D. Spector, M. Delannoy, S. Grant, D. Hanahan, and S. Baekkeskov β-cell lines derived from transgenic mice expressing a hybrid insulin gene-oncogene Proc. Natl. Acad. Sci. USA 85 1988 9037 9041
15. N. Ferrara, H.P. Gerber, and J. LeCouter The biology of VEGF and its receptors Nat. Med. 9 2003 669 676
16. D. Hanahan Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes Nature 315 1985 115 122
17. D. Hanahan, and J. Folkman Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 1996 353 364
18. K. Hattori, B. Heissig, Y. Wu, S. Dias, R. Tejada, B. Ferris, D.J. Hicklin, Z. Zhu, P. Bohlen, and L. Witte Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment Nat. Med. 8 2002 841 849
19. S. Hiratsuka, O. Minowa, J. Kuno, T. Noda, and M. Shibuya Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice Proc. Natl. Acad. Sci. USA 95 1998 9349 9354
20. J. Holash, P.C. Maisonpierre, D. Compton, P. Boland, C.R. Alexander, D. Zagzag, G.D. Yancopoulos, and S.J. Wiegand Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF Science 284 1999 1994 1998
21. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, and E. Holmgren Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N. Engl. J. Med. 350 2004 2335 2342
22. M. Inoue, J.H. Hager, N. Ferrara, H.P. Gerber, and D. Hanahan VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic β cell carcinogenesis Cancer Cell 1 2002 193 202
23. C. Jolicoeur, D. Hanahan, and K. Smith T cell tolerance towards a transgenic β cell antigen and transcription of endogenous pancreatic genes in the thymus Proc. Natl. Acad. Sci. USA 91 1994 6707 6711
24. J.A. Joyce, A. Baruch, K. Chehade, N. Meyer-Morse, E. Giraudo, F.Y. Tsai, D.C. Greenbaum, J.H. Hager, M. Bogyo, and D. Hanahan Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis Cancer Cell 5 2004 443 453
25. J.A. Joyce, C. Freeman, N. Meyer-Morse, C.R. Parish, and D. Hanahan A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer Oncogene 24 2005 4037 4051
26. R.S. Kerbel, J. Yu, J. Tran, S. Man, A. Viloria-Petit, G. Klement, B.L. Coomber, and J. Rak Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches Cancer Metastasis Rev. 20 2001 79 86
27. G. Klement, S. Baruchel, J. Rak, S. Man, K. Clark, D.J. Hicklin, P. Bohlen, and R.S. Kerbel Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity J. Clin. Invest. 105 2000 R15 R24
28. W.P. Leenders, B. Kusters, K. Verrijp, C. Maass, P. Wesseling, A. Heerschap, D. Ruiter, A. Ryan, and R. de Waal Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option Clin. Cancer Res. 10 2004 6222 6230
29. A. Luttun, M. Tjwa, L. Moons, Y. Wu, A. Angelillo-Scherrer, F. Liao, J.A. Nagy, A. Hooper, J. Priller, and B. De Klerck Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 Nat. Med. 8 2002 831 840
30. T. Matsumoto, S. Bohman, J. Dixelius, T. Berge, A. Dimberg, P. Magnusson, L. Wang, C. Wikner, J.H. Qi, and C. Wernstedt VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis EMBO J. 24 2005 2342 2353
31. A.A. Miles, and E.M. Miles Vascular reactions to histamine, histamine-liberator and leukotaxine in the skin of guinea-pigs J. Physiol. 118 1952 228 257
32. K.D. Miller, C.J. Sweeney, and G.W. Sledge Jr. The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era Ann. Oncol. 14 2003 20 28
33. K.D. Miller, C.J. Sweeney, and G.W. Sledge Jr. Can tumor angiogenesis be inhibited without resistance? EXS 94 2005 95 112
34. P. Mombaerts, J. Iacomini, R.S. Johnson, K. Herrup, S. Tonegawa, and V.E. Papaioannou RAG-1-deficient mice have no mature B and T lymphocytes Cell 68 1992 869 877
35. S. Parangi, M. O'Reilly, G. Christofori, L. Holmgren, J. Grosfeld, J. Folkman, and D. Hanahan Antiangiogenic therapy of transgenic mice impairs de novo tumor growth Proc. Natl. Acad. Sci. USA 93 1996 2002 2007
36. A. Passaniti, R.M. Taylor, R. Pili, Y. Guo, P.V. Long, J.A. Haney, R.R. Pauly, D.S. Grant, and G.R. Martin A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor Lab. Invest. 67 1992 519 528
37. S. Pennacchietti, P. Michieli, M. Galluzzo, M. Mazzone, S. Giordano, and P.M. Comoglio Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene Cancer Cell 3 2003 347 361
38. F. Pezzella, U. Pastorino, E. Tagliabue, S. Andreola, G. Sozzi, G. Gasparini, S. Menard, K.C. Gatter, A.L. Harris, and S. Fox Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis Am. J. Pathol. 151 1997 1417 1423
39. C.W. Pugh, and P.J. Ratcliffe Regulation of angiogenesis by hypoxia: role of the HIF system Nat. Med. 9 2003 677 684
40. S.Y. Rabbany, B. Heissig, K. Hattori, and S. Rafii Molecular pathways regulating mobilization of marrow-derived stem cells for tissue revascularization Trends Mol. Med. 9 2003 109 117
41. E. Ryschich, J. Schmidt, G.J. Hammerling, E. Klar, and R. Ganss Transformation of the microvascular system during multistage tumorigenesis Int. J. Cancer 97 2002 719 725
42. A. Sawano, S. Iwai, Y. Sakurai, M. Ito, K. Shitara, T. Nakahata, and M. Shibuya Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans Blood 97 2001 785 791
43. M. Shibuya Structure and function of VEGF/VEGF-receptor system involved in angiogenesis Cell Struct. Funct. 26 2001 25 35
44. P.S. Steeg Angiogenesis inhibitors: motivators of metastasis? Nat. Med. 9 2003 822 823
45. J.C. Yang, L. Haworth, R.M. Sherry, P. Hwu, D.J. Schwartzentruber, S.L. Topalian, S.M. Steinberg, H.X. Chen, and S.A. Rosenberg A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N. Engl. J. Med. 349 2003 427 434
46. J.L. Yu, J.W. Rak, B.L. Coomber, D.J. Hicklin, and R.S. Kerbel Effect of p53 status on tumor response to antiangiogenic therapy Science 295 2002 1526 1528